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Abstract
Background: One of the major challenges associated with our ageing population is the increasing incidence of
age-associated cognitive decline, which has significant implications for an individual’s ability to lead a productive
and fulfilling life. In pure economic terms the costs of ageing reflects decreased productivity and engagement with
the workforce. The maintenance of brain health underpinning intact cognition is a key factor to maintaining a
positive, engaged, and productive lifestyle. In light of this, the role of diet, including supplementation with
nutritional and even pharmacological interventions capable of ameliorating the neurocognitive changes that occur
with age constitute vital areas of research.
Methods: In order to reduce cognitive ageing, the ARC longevity intervention (ARCLI) was developed to examine
the effects of two promising natural pharmacologically active supplements on cognitive performance. ARCLI is a
randomized, placebo-controlled, double-blind, 3-arm clinical trial in which 465 participants will be randomized to
receive an extract of Bacopa monnieri (CDRI08 300 mg/day), Pycnogenol (150 mg/day), or placebo daily for 12
months. Participants will be tested at baseline and then at 3, 6 and 12 months post-randomization on a wide
battery of cognitive, neuropsychological and mood measures, cardiovascular (brachial and aortic systolic and
diastolic blood pressures as well as arterial stiffness), biochemical (assays to measure inflammation, oxidative stress
and safety) as well as genetic assessments (telomere length and several Single Nucleotide Polymorphisms). The
primary aim is to investigate the effects of these supplements on cognitive performance. The secondary aims are
to explore the time-course of cognitive enhancement as well as potential cardiovascular and biochemical
mechanisms underpinning cognitive enhancement over the 12 months of administration.
ARCLI will represent one of the largest and most comprehensive experimental clinical trials in which supplements
are administered to elderly participants. Results from ARCLI may help develop novel preventative health practices
and nutritional/pharmacological targets in the elderly for cognitive and brain health.
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Background and Rationale
With increasing life expectancies and the maturation of
the “baby boom” generation, adapting to the challenges
posed by the ageing population has been identified as
one of the major issues facing contemporary society [1].
Human ageing has significant societal, economic, health
and, importantly, personal costs. In pure economic
terms the costs of ageing reflects decreased productivity
as well as increased levels of reliance on public services
for health and social support but this also has obvious
ramifications for older people’s ability to lead fulfilling
lives. Increasing age is associated with a cluster of ill-
nesses many involving oxidative stress and low level
chronic inflammation. These include cardiovascular and
respiratory disease and, importantly neurological condi-
t i o n ss u c ha sP a r k i n s o n ’s disease (PD) and Alzheimer’s
disease (AD).
What is Cognitive Ageing?
Individual age-related changes in cognition vary greatly.
However research in cognitive aspects of ageing (typi-
cally in 60 to 90 year-olds) has identified consistent defi-
cits in: reasoning and decision making; spatial abilities;
perceptual-motor and cognitive speed; and most
robustly memory (e.g. [2]). Longitudinal studies of aged
populations illuminate the time-course of cognitive dete-
rioration. Using 5 to 10 year re-test intervals significant
decrements across most cognitive capacities become evi-
dent. A recent review of longitudinal ageing studies con-
cludes that crystallized intelligence (e.g., factual
knowledge) remains intact until late ageing whereas
measures of speed, information processing and aspects
of memory (e.g., working memory) are more sensitive to
decline from age 60 [2].
Brain Ageing and Oxidative Stress
Neuroimaging studies reveal that increasing age is reli-
ably associated with ventricular enlargement, reduction
in gross brain volume, reductions in frontal and tem-
poro-parietal brain volume, higher levels of cortical atro-
phy, and increased white matter hyperintensities [3].
Ultimately, shrinkage of cortical volume reduces cogni-
tive capacity [4] and age-related increases in neuro-
pathological events such as beta-amyloid protein
deposition and formation of neurofibrillary tangles
represent significant risk factors for cognitive decline
and AD. Neuropathological events such as beta-amyloid
deposition are not exclusive to neurodegenerative disor-
ders such as AD, in fact occurring in a large proportion
of cognitively intact individuals. For example, in one
study the proportion of non-clinical subjects with beta-
amyloid deposits ranged from 3% in a 36-40 age group
to 75% in a 85+ age group [5].
Alongside age-associated cortical degeneration [4],
there exist numerous microscopic insults related to oxi-
dative stress and free radical damage. Free radicals are
molecules with unpaired electrons. These molecules are
highly unstable and can cause damage to proteins, lipids,
carbohydrates and nucleotides [6]. Free radicals formed
in the brain produce significant cellular damage, and
mediate processes which result in neural cell death on
large scales [7]. Between 95%a n d9 8 %o ff r e er a d i c a l s
and Reactive Oxygen Species (ROS) (O2
￿-,H O
￿,H 2O2)
are formed by mitochondria as by-products of cellular
respiration. Studies of mitochondria isolated from the
brain show that 2-5% of total oxygen consumed yields
ROS [8], these highly reactive molecules make a signifi-
cant contribution to the peroxidation of principal cell
structures (e.g. membrane lipids) [8]. Brain tissue is parti-
cularly susceptible due to it’s disproportionately high
metabolic rate and levels of oxygen, the cytotoxic actions
of glutamate, and it’s high concentrations of peroxidisa-
ble unsaturated fatty acids [7]. Ageing decreases the
brain’s ability to combat the actions of free radicals and
is associated with increased levels of pro-oxidant media-
tors and decreased antioxidant levels [9]. The relation-
ship between cognition and oxidative stress is evident in
the extensive damage caused by free radicals in age-
related neurological conditions [10,11], and animal mod-
els of age-related oxidative injury with central cognitive
and behavioural impairments [12]. Concurrent with the
normal age-related cognitive changes are increases in the
formation of brain ROS resulting in significant damage
to DNA, proteins and in particular membrane lipids [13].
Although multiple factors precipitate oxidative stress
throughout the body, the brain is particularly vulnerable
and its cumulative effects may account for the delayed
o n s e ta n dp r o g r e s s i v en a t u r eo fA l z h e i m e r ’sa n dP a r k i n -
son’s dementias, as well as normal age-related mental
deterioration [10].
Antioxidants and Cognition
The central role of oxidative stress in age-related cogni-
tive decline and neurodegenerative diseases has driven
numerous studies examining the potential benefits of
antioxidants in altering, reversing, or forestalling neuro-
nal and behavioural changes (e.g. [14]). Anti-oxidant
supplementation results in improved cognition and
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oxidative insult to neural structures [15]. Human
research in this area is largely limited to epidemiological
studies. These have identified positive associations in
aged individuals between biological levels of dietary anti-
oxidants (vitamins E and C) and working memory mea-
sures including the Wechsler Memory test [16]. Less
reliable than biological measures, large scale studies
(3000+ participants) have also identified positive rela-
tionships between dietary intake of vitamin C and E and
standardized memory measures [17]. While these non-
clinical trials do not demonstrate causality, the consen-
sus that memory is the main cognitive variable affected
by antioxidant status is consistent with patterns of age-
related cognitive decline and the in vivo neuroanatomy
of lipid peroxidation [18].
Given the consequences of a burgeoning ageing popu-
lation, the role of supplementation with nutritional and
pharmacological interventions capable of ameliorating
the neurocognitive changes that occur with age consti-
tute vital areas of research.
Treatments to Reduce or Ameliorate Brain Ageing
(i) Pycnogenol Neural cells have three systems of protec-
tion and repair in response to oxidative stress; 1) Enzy-
matic antioxidants (superoxide dismutase, catalase,
peroxidases); 2) Radical scavenging lipid-soluble (toco-
pherols, flavonoids, carotenoids) and water- soluble
(ascorbate, glutathione) antioxidants; and 3) repair pro-
teases and phospholipases [7]. Pycnogenol
® is a patented
concentrate consisting of condensed flavonoids isolated
from Maritime Pine bark. Extensive reviews by Packer
et al [19] and Rohdewald [20] have established the anti-
oxidant activity of Pycnogenol in simplified assay sys-
tems, cultured cell models, and perfused organs. There is
evidence that Pycnogenol prolongs the lifetime of the
ascorbate antioxidant and stimulates the synthesis of
antioxidant enzymes inside arterial cells [21]. The estab-
lished neuroprotective properties of flavonoids strongly
advocate their use in intervention strategies [22]. Of
these, Pycnogenol is particularly promising, having been
studied extensively in the context of protecting against
oxidative damage to specific neural systems. Kobayashi
[23] reported that Pycnogenol had neuroprotective prop-
erties in HT-4 neuronal cells subjected to glutamate-
induced cytotoxicity (one of the principle sources of ROS
in the brain [10]. Similarly Liu [24] and Peng [25] found
Pycnogenol to inhibit beta-amyloid apoptosis of neurons
and vascular cells, both of which are oxidative processes
that accumulate with age, and are pathological features of
AD. In vivo supplementation to aged animals [26] results
in biological and behavioural changes consistent with the
slowing of age-related decline in physiology, learning and
memory. Additionally 6 wk Pycnogenol supplementation
to humans resulted in significantly reduced serum low
density lipoprotein and increased plasma oxygen radical
absorbance capacity (ORAC) [27] - a convenient
although non-specific measure of in vivo antioxidant
activity [28].
(ii) Bacopa Monniera (L.) Wettst. (syn. Bacopa mon-
niera Hayata & Matsum) has been used in traditional
Ayurvedic medicine for various indications including
memory decline, inflammation, pain, pyrexia, epilepsy and
as a sedative [29]. Bacopa contains Bacoside A and Baco-
side B which are steroidal saponins believed to be essential
for the clinical efficacy of the product. While Bacopa has
been reported to have many actions, its memory enhan-
cing effects have attracted most attention and are sup-
ported by the psychopharmacology literature. Behavioural
studies in animals have shown that Bacopa improves
motor learning, acquisition and retention, and delay
extinction of newly acquired behaviour [30]. Although the
exact mechanisms of action remain uncertain, evidence
suggests that Bacopa may modulate the cholinergic system
and/or have antioxidant and metal chelating effects
[31,32]. Bacopa m a ya l s oh a v ea n t ii n f l a m m a t o r y[ 3 3 ] ,
anxiolytic and antidepressant actions [34,35], relaxant
properties in blood vessels [36] and adaptogenic activity
[37]. Chronic administration of Bacopa inhibits lipid per-
oxidation in the prefrontal cortex, striatum and hippocam-
pus via a similar mechanism to vitamin E [38]. In an
animal model of AD, there was a dose-related reversal by
Bacopa of cognitive deficits produced by the neurotoxins
colchicine and ibotenic acid [32]. In rodents, Bacopa
inhibited the damage induced by high concentrations of
nitric oxide in astrocytes [39]. Memory deficits following
cholinergic blockade by scopolamine were reversed by
Bacopa treatment. In animal studies Bacopa reduced lipid
peroxidation induced by FeSO4 and cumene hydroperox-
ide indicating that, similarly to the chelating properties of
EDTA, it acts at the initiation level by chelating Fe
++ [40].
More recently in transgenic mice, Bacopa supplementa-
tion reduced specific amyloid peptides by up to 60% whilst
also improving memory performance [41]. Thus, Bacopa
appears to have multiple modes of action in the brain all
of which may be useful in ameliorating cognitive decline
in the elderly. These include: (i) direct pro-cholinergic
action; (ii) anti-oxidant (flavonoid) activity; (iii) metal che-
lation; (iv) anti-inflammatory effects; (v) improved blood
circulation; (vi) adaptogenic activity; and (vii) removal of
b-amyloid deposits. In contrast to anti-oxidants such as
Vitamin C and E, and specific anti-oxidants such as Pyc-
nogenol, the polypharmacological actions of Bacopa
potentially act on several pathological changes in elderly
brains in concert. This potential is supported by a limited
number of clinical trials into the neurocognitive effects of
Pycnogenol and, to a greater extent, Bacopa. Both sub-
stances are capable of improving memory functioning in
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working memory [42] and Bacopa preferentially enhan-
cing secondary memory (reviewed in Pase et al.[43]). In
both cases effects are evident at three months of daily
administration, but not earlier.
Design and methodology
Design
ARCLI is a randomized, double-blind, placebo-con-
trolled, 3-arm parallel-groups clinical trial with partici-
pants randomized to receive Bacopa, Pycnogenol or a
placebo.
Aims and study hypotheses
Extending upon preliminary findings [42,44,45], the pri-
mary aim of the current study is to examine the indivi-
dual chronic 12 month effects of Bacopa (300 mg daily),
and Pycnogenol (150 mg daily) on cognitive performance
i nah e a l t h ye l d e r l yp o p u l a t i o n .T h es e c o n d a r ya i m so f
the current study are two fold. Firstly, to investigate the
time course of cognitive ehancement with follow-up test-
ing at 3, 6 and 12 months. Secondly, to examine putative
mechanisms underpinning any cognitive enhancing
actions of the supplements by examining relationships
between cognitive, biological (biochemical and genetic)
and cardiovascular variables over the 12 months. By
examining the interrelationship between inflammation,
oxidative stress, cardiovascular health and cognitive per-
f r o m a n c e ,t h ec u r r e n ts t u d ya ims to identify modifiable
risk factors for cognitive decline that can be targeted by
supplementation. It is hypothesized that all supplements
will improve measures of cognitive performance, relative
to placebo, at all time points with the greatest cognitive
effects observed at 12 months.
Centres
ARCLI will be conducted at the Centre for Human Psy-
chopharmacology, Swinburne University, Melbourne,
Australia. In the first year approximately 1/3 of the
cohort will be enrolled. In years 2 and 3 additional
recruitment will occur at the University of Western Syd-
ney (Sydney, Australia).
Participants
A total of 465 healthy, elderly participants aged between
60 and 75 years will take part in the study. This
restricted age range was chosen due to the large varia-
tion in cognitive abilities and trajectories associated with
ageing. Participants will be randomized to receive one of
three daily treatments for 12 months: (a) 300 mg
Bacopa (KeenMind CDRI 08 extract); (b) 150 mg Pyc-
nogenol; or (c) placebo. Participants will be excluded
from participation if they are a current smoker; have a
psychiatric or neurological disease; significant endocrine,
gastrointestinal or cardiovascular disorder; other disor-
der affecting food metabolism; recent history (past 5
years) of chronic/severe illness (longer than 6 weeks);
current regular alcohol use exceeding 14 standard drinks
per week for women and 28 standard drinks per week
for men; vision that is not corrected to normal. To be
eligible, participants cannot be taking psychoactive med-
ication including, antidepressants, antipsychotics, anxio-
lytics, cholinesterase inhibitors, illicit drugs or significant
cognitive enhancing drugs (e.g. chronic intake of sub-
stances such as Ginkgo). Participants who are irregular
users of vitamin or herbal supplements will be asked to
stop taking them for the duration of the trial. Partici-
pants who are regular users (defined as daily intake for
greater than 3 months) of vitamins or herbal supple-
ments will be asked to maintain the same habits
throughout the trial. Participants with either global cogni-
tive impairment or significant levels of depressive symp-
toms, as determined by a score < 24 on the Mini Mental
State Examination (MMSE) or a score > 19 on the Geria-
tric Depression Scale respectively, will be excluded. To
ensure that participants do not have probable dementia,
those scoring between 24-26 on the MMSE will be admi-
nistered the Dementia Rating Scale II (DRS-II). Any ques-
tionable cases on the DRS-II will be discussed by the
ARCLI participant safety committee for agreement on
eligibility. The study was ethically approved by the Swin-
burne University Human Research Ethics Committee
(project number 2010/106) and all participants will pro-
vide written informed consent. The trial has been regis-
tered with the Australian and New Zealand Clinical Trials
Registry (ACTRN12611000487910).
Procedure
Eligible participants are required to attend five testing ses-
sion. An overview of the testing sessions is provided in the
clinical trial flow chart (Figure 1). During the first session,
participants are screened for eligibility and a detailed his-
tory is taken. Eligible participants are then asked to give
blood and to complete the cognitive test batteries multiple
times. This allows the participant to familiarize themselves
with the cognitive tasks and minimises practice effects (as
well as establishing that the participant lies within estab-
lished norms for their age group). Cognitive data obtained
during the training visit will not be included in statistical
analysis. Visit 2 involves baseline assessment of all mea-
sures and randomization to treatment. Participants are to
commence taking their assigned treatment on the day fol-
lowing their baseline assessment. As depicted in Figure 1,
visits 3 to 5 involve follow-up assessment at 3, 6 and 12
months post randomization. At the 12 month assessment,
participants will be asked to return any remaining supple-
ments, such that they can be counted enabling the investi-
gators to estimate compliance to treatment.
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The sample size for this study is 465 participants with 155
participants in each arm. Previous studies using Bacopa
and Pycnogenol have reported statistical significance on
measures of cognition with approximately 100 participants
in each of these studies respectively [42,44]. Based on
these previous studies, the current sample size of 465
ensures adequate power to detect a significant effect 80%
of the time when conducting two-tailed tests using 95%
confidence even when allowing for a 10-20% attrition rate.
Treatments
(a) The Bacopa supplement used in ARCLI is an extract
of Bacopa monnieri called CDRI08 and is commercially
available as KeenMind™ (Flordis). This product is man-
ufactured from the stems, leaves and roots of Bacopa
and is extracted with 50% ethanol. It is standardized to
contain active bacosides at levels of 55% ± 5%. This
extract has previously been shown to enhance cognitive
performance at this dosage after 3 months of supple-
mentation [44,45].
(b) Pycnogenol (Horphag Research, Geneva, Switzer-
land) is a patent extract made exclusively from the bark
of French maritime pine trees (Pinus pinaster). Pycno-
genol contains consistent proportions of bioflavonoids
and is standardized to contain 70 ± 5% procyanidins.
This dosage of Pycnogenol has previously been shown
to enhance memory performance after 3 months of sup-
plementation [42].
Randomization and safety
An independent researcher (Medical practitioner) located
at an independent university will be responsible for the
randomization of the study treatments and will chair the
safety committee. Participants will be randomly assigned
to one of the three treatment groups according to a Latin
square design. Randomization codes will be kept in a
sealed opaque envelope in a secure safe and will only be
opened in case of emergency.
Primary outcome
The primary study outcome is the effect of supplementa-
tion on cognitive performance as measured by a battery of
well validated and highly sensitive cognitive tests. These
tests will be implemented at baseline and all follow-up
time points (3, 6 and 12 months post baseline). This bat-
tery will include all tasks from the Cognitive Drug
Research (CDR) Computerized Assessment System and
selected tasks from the Swinburne University Computer-
ized Cognitive Assessment Battery (SUCCAB). Table 1
lists the cognitive measures assessed by the CDR and
SUCCAB batteries. Wechsler intelligence (Wechsler
Abbreviated Scale of Inteligence-WASI) will also be admi-
nistered as both an estimate of pre-morbid intelligence as
well as a factor to determine whether IQ predicts response
to any of the supplements.
The CDR battery has been used in well over 1000 clini-
cal trials world wide, is well validated, and has been
shown to be sensitive to the effects of several natural sup-
plements including Bacopa and Pycnogenol [42,44]. The
SUCCAB is sensitive to the effects of age-associated cog-
nitive decline and has been recommended for use when
assesing cognitive changes following nutraceutical sup-
plementation [46]. The SUCCAB has also been shown
sensitive to the effects of a pine bark extract similar to
Pycnogenol [47]. Both the CDR and SUCCAB provide
detailed assessments of memory performance (both short
and long term), a domain of cognition expected to be
modulated by treatment. The cognitive demand battery
[48] will be implemented to assess the effects of supple-
mentation on cognitive effort and fatigue whilst the
MMSE [49] will be used as a dementia screening tool at
intake and to monitor the effects of treatment on global
cognitive decline (after randomization). The Inspection
Time task [50] and Hick Reaction Time paradigm [51]
Figure 1 ARCLI protocol flow diagram.
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assessment of mental speed which has been shown to
slow with increasing age.
Secondary outcomes
A wide range of psychological, cardiovascular, biochem-
ical and genetic measures will also be collected at differ-
ent time points as part of ARCLI. These are described
below and listed in Table 2.
Mood, health and dietary habits
Numerous self-report questionnaires will be used to
assess mood and general health. Depressive symptoms
and state-trait anxiety will be measured with the Beck
Depression Inventory II (BDI-II) [52] and the Spielber-
ger State-Trait Anxiety Inventory [53] respectively.
Further assessment of mood will be performed with the
Profile of Mood Scales [54] and the Bond and Lader
Visual Analogue Scales [55]. Throughout the trial, gen-
eral health, fatigue and sleep quality will be assessed
with the General Health Questionnaire [56], Chalder
Fatigue Scale [57] and the Leeds Sleep Evaluation Ques-
tionnaire [58] respectively. Dietary habits will be inferred
from an in-house Food Frequency Questionnaire.
Cardiovascular
Brachial pressures, aortic pressures and carotid-femoral
P u l s eW a v eV e l o c i t y( P W V )a r en o to n l ya s s o c i a t e dw i t h
cardiovascular disease risk and mortality [59,60] but also
cognitive performance and decline [61,62]. These vari-
ables can all be modified by diet and lifestyle changes
[63-65] and will therefore be monitored throughout the
trial as one possible mechanism by which the study sup-
plements improve brain function. Brachial blood pressure
Table 1 Cognitive domains measured by CDR and SUCCAB tests
CDR SUCCAB Hick RT Inspection Time
Simple RT Stroop Colour-Word Simple Decision Time Perceptual Speed
Choice RT Spatial Working Memory Simple Movement Time
Spatial WM Contextual Memory 2 Choice Decision Time
Numeric WM Immediate/Delayed Recognition 2 Choice Movement Time
Picture Presentation 4 Choice Decision Time
Immediate Word Recall 4 Choice Movement Time
Digit Vigilance 8 Choice Decision Time
Delayed Word Recall 8 Choice Movement Time
Word Recognition
Picture Recognition
Rapid Visual Information Processing
CDR = Cognitive Drug Research, SUCCAB = Swinburne University Computerized Cognitive Assessment Battery, RT = Reaction Time, WM = Working Memory
Table 2 Summary of the secondary outcomes implemented in ARCLI across all time points
Training Baseline 3 month 6 month 12 month
Screening Medical history & screen
(GDS, MMSE, DRS-II)
Demographic Q
Medical screen (ie BMI,
MMSE, medication use)
Medical screen (ie BMI,
MMSE, medication use)
Medical screen (ie BMI,
MMSE, medication use)
Medical screen (ie BMI,
MMSE, medication use)
Biochemical Fasting Glucose &
Insulin*
APOE & SNP
F2 Isoprostanes
Cytokines* & CRP
MBA
Telomere length
F2 isoprostanes
Cytokines* & CRP
MBA
- F2 isoprostanes
Cytokines* & CRP
MBA
Telomere length
Cardiovascular - Brachial BP
Aortic BP
carotid-femoral PWV
Brachial BP
Aortic BP
carotid-femoral PWV
Brachial BP
Aortic BP
carotid-femoral PWV
Brachial BP
Aortic BP
carotid-femoral PWV
Health FFQ
Chalder Fatigue
Leeds Sleep evaluation
Trait anxiety
General Health Q
State anxiety
Leeds Sleep Evaluation
BDI-II
POMS
General Health Q
State anxiety
Leeds Sleep Evaluation
BDI-II
General Health Q
State anxiety
Leeds Sleep Evaluation
BDI-II
FFQ
General Health Q
State anxiety
Leeds Sleep Evaluation
BDI-II
Other NEO PI-R
WASI
Estimate of compliance
* = Analysis performed for morning participants only
GDS = Geriatric Depression Scale, MMSE = Mini Mental State Examination, DRS = Mattis Dementia Rating Scale, Q = Questionnaire, APOE = Apolipoprotein E,S N P
= Single Nucleotide Polymorphisms, WASI = Wechsler Abbreviated Scale of Intelligence FFQ = Food Frequency Questionnaire, NEO PI-R = NEO Personality-Inventory
Revised, POMS = Profile of Mood States, BMI = Body Mass Index, CRP = C Reactive Protein, MBA = Multiple Blood Analysis, BP = Blood Pressure, PWV = Pulse
Wave Velocity
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clinically validated automated sphygmomanometer.
Applanation tonometry of the radial artery will be used
to estimate aortic pressures and wave reflections using a
non-invasive SphygmoCor device. The same Sphygmo-
Cor device will be used to measure PWV through appla-
nation of the carotid and femoral arteries. In addition to
this assessment, cerebral and common carotid blood flow
velocity and endothelial dependent vasodilation of the
brachial artery may be measured on a subset of partici-
pants using transcranial Doppler and flow mediated dila-
tion respectively.
Biochemical
Pre-randomization, one off biochemical assessment will
be conducted to measure glycated haemoglobin
(HbA1c) and insulin levels. Measurement of blood glu-
cose and insulin will provide a measure of baseline glu-
coregulatory efficiency and control, which may
contribute to age-related cognitive decline [66]. At both
baseline and selected follow-up time points, biochemical
markers of oxidative stress, inflammation and safety pro-
filing will be measured through high sensitivity C-Reac-
tive Protein, F2-Isoprostanes, inflammatory cytokines
(e.g. TNF-a, IL-2, IL-4, IL-6, IL-10 & IFN-gamma) and
Liver Function Tests.
Genetic
Blood collected pre-randomization will also be used to
assess a platform of Single Nucleotide Polymorphisms
thought to be related to cognitive/brain function, gen-
eral health or response to treatment. This will include
assessment of the APOE4 allele, which is associated
with an increased risk of AD [67] and cognitive decline
in normal elderly [68] but also more than 100 targeted
polymorphisms including BDNF, cytokines amongst
others. Genotyping will allow investigation of whether
certain polymorphisms affect response to treatment or
show differential relationships with the cognitive and
biological variables. Telomere length (a marker of
genetic damage) will also be assessed at baseline and 12
months to investigate whether any of the treatments
modulate telomere shortening over the duration of the
study.
Analysis
The primary analysis will investigate the effects of treat-
ment on all cognitive outcomes over the course of the
study using Analysis of Variance (ANOVA) techniques.
Other more powerful statistical techniques such as lin-
ear mixed modelling and intention to treat analysis will
be considered. Similar statistical techniques will be used
to investigate the effects of treatment on the secondary
outcomes. Pearson’s correlation coefficients will be used
to investigate whether any improvements in cognition
are related to improvements in other variables of inter-
est such as biochemical, cardiovascular or mood/health
factors. Correlations and regression models may be used
to examine baseline associations between variables.
Results will be considered statistically significant at p <
0.05 corrected for multiple cognitive factors (primary
outcome variables) or p < .05 for secondary outcome
variables.
Covariates such as age, gender and baseline cognitive
screening measures (e.g., MMSE and Wechsler intelli-
gence) will be adjusted for in the analyses. Results will
be presented as appropriate effect sizes with a measure
of precision (95% confidence intervals). Compliance to
treatment will be analysed by counting each participants
remaining supplements once they have completed the
trial.
Safety and Data Monitoring Committee
A data and safety committee will comprise the study GP
(Prof Myers), the study nurse, the Chief Investigator
(Prof Stough) and a medical officer attached to the Cen-
tre for Human Psychopharmacology but not otherwise
part of ARCLI.
Conclusions
Given our currently ageing population, research addres-
sing the issue of cognitive decline in aged individuals is
critical. This issue is further reinforced by the fact that
such cognitive decline frequently precedes various forms
of dementia. The proposed study will be the largest and
most definitive yet assessing the role of the cognitive
enhancers Bacopa and Pycnogenol on combined cogni-
tive and biological measures in elderly participants.
Improving the cognitive functioning of elderly citizens
will have significant benefits at the societal, economic
and personal levels. Cognitive capacity is strongly corre-
lated with performance in many occupations and ameli-
orating the decline in fluid intelligence, memory and
reasoning will allow many elderly people to continue to
work and to continue to contribute to our society as
they age. Coupled with the large sample size, ARCLI is
one of the most definitive studies to explore the effects
of Bacopa and Pycnogenol on cognitive ageing. Results
from this study may help guide policies and preventative
health practices in the elderly.
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Wave Velocity; Q: Questionnaire; RCT: Randomized, Controlled Trial; ROS:
Reactive Oxygen Species; RT: Reaction Time; SNP: Single Nucleotide
Polymorphisms; SUCCAB: Swinburne University Computerized Cognitive
Assessment battery; WASI: Wechsler Abbreviated Scale of Intelligence; WM:
Working Memory.
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